Across TCGA pan-cancer cohorts, GOLGA6L9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GOLGA6L9 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher GOLGA6L9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6L9 expression acts as an unfavorable survival marker.

ESCA are the cancer types where GOLGA6L9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.277	0.707	.004	24	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: GOLGA6L9 tumor-vs-normal RNA expression · all GOLGA6L9 data types